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j Abstract Objectives Executive
function deficits have been de-
scribed in early and continuously
treated patients with phenylke-
tonuria (PKU). The aim of this
study was to examine performance
on executive function tasks of
treated patients with PKU diag-
nosed by 2 years of age. Patients
and methods Ten patients with
PKU and normal intelligence score
who were diagnosed before the age
of 2 years and subsequently trea-
ted continuously, were compared
with 15 typically developing con-
trol children on a battery of neu-
ropsychological tests, including
the tower of London (TOL), con-
tinuous performance test (CPT),
and Stroop test. Results PKU
cases showed significantly poorer
performance on the TOL task
compared to the control group
with the difference being signifi-
cant in the first three levels of the
test. With the CPT, PKU cases had
significantly more omission errors
than control subjects. On the
Stroop test there was no statisti-
cally significant difference be-
tween the groups. No significant
correlation was found between the
concurrent serum phenylalanine
(Phe) level and results of the
executive tests in PKU patients.
Conclusion This study identified
executive dysfunction in early-
treated PKU patients with normal
IQ, particularly in the planning
and attention domains. Further
studies are required to compare
the results with those from other
neurodevelopmental disorders
such as ADHD and autism, to
establish whether the pattern of
findings is specific to PKU.
j Key words early-treated phen-
ylketonuria – executive func-
tion – neuropsychology –
serum phenylalanine
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Introduction
Phenylketonuria (PKU) is the most frequent inborn
error of aminoacid metabolism, which was first
described by the Norwegian physician Dr. Asbørn
Følling in 1934 [9]. It is estimated to affect 1 in 10,000
to 12,000 live births in different populations [21].
Early diagnosis and treatment has made classical PKU
phenotype a matter of historical rather than current
interest [25]. However, a study performed in the
institutions for the developmentally delayed in Teh-
ran, Iran, revealed the prevalence of hyper-phenylal-
aninemia (HPA) to be 2.75% [26]; and the incidence
of PKU in Iran is estimated to be one in 3,672 [14].
Despite the relatively high levels of PKU in Iran,
which are the highest reported rates in the literature,
screening programs have yet to be widely instituted in
Iran. Consequently, diagnosis is delayed in the
majority of affected individuals and the low-phenyl-
alanine regimen is often not introduced in time to
prevent development of the clinical disorder. There
are therefore only a few patients in Iran with early and
continuously treated PKU within the normal range of
intelligence, as measured by IQ. Untreated PKU is the
most common biochemical cause of mental retarda-
tion, with excessive amounts of aminoacid phenylal-
anine (Phe) in the brain leading to severe learning
disabilities, neurological impairments and behavioral
problems including hyperactivity, inattention,
aggressiveness and autistic features [24].
From a different perspective, the range of deficits
associated with PKU suggests that the disorder may
represent an excellent model for the study of cognitive
processes during early development. Even in infants
and young children with early treated PKU, subtle yet
specific cognitive deficits occur which are not typi-
cally detected using traditional IQ measures, giving
rise to a Prefrontal Dysfunction Hypothesis [5]. Pre-
vious studies find evidence of deficits in working
memory and other high-level reasoning skills even in
the presence of normal IQ [5, 31]. The theoretical
basis for the presence of a prefrontal dysfunction
syndrome in PKU is that the metabolic disorder leads
to a deficiency in monoaminergic neurotransmitters,
causing dopamine depletion in the prefrontal cortex,
which in turn results in impaired executive functions
[6, 20]. Executive functions encompass the ability to
maintain a problem-solving set that is appropriate for
goal acquisition, including formulation, strategic
planning, self-monitoring, mental flexibility, and the
ability to change strategies in response to new infor-
mation. In fact, EF can be viewed as an umbrella term
for a set of cognitive functions critically supported
by the pre-frontal cortex including regulation of
attention, inhibition of inappropriate responses, co-
ordination of information in working memory and
cognitive flexibility [7, 16]. Impairments in EF have
been found in patients with a wide range of neuro-
developmental disorders including autism spectrum
disorders (ASD), attention deficit hyperactivity
disorder (ADHD) [11] and the fragile-X syndrome
[12].
Assessment of the impact of elevated Phe concen-
trations on the prefrontal cortex in patients with
early-treated PKU has produced diverse conclusions
about the presence or specificity of executive function
deficits [10, 29]. Mazzocco found no evidence of
prefrontal dysfunction while studying PKU patients
aged 6–13 years, suggesting that the cognitive deficits
observed in younger children (preschool children)
represent an early developmental delay rather than
persistent developmental deficit [17]. In another
study, Feldmann compared 42 adolescent patients
with PKU to diabetic patients on a variety of measures
of executive function (Wisconsin Card Sorting Test,
Stroop Task and Test d-2) and did not find specific
frontal deficits in the patient group [8].
In contrast to Mazzocco’s findings, White and col-
leagues in a study on 20 PKU subjects aged 6–17 years
demonstrated that PKU related deficits in working
memory were prominent later in childhood. Thus, they
suggest a developmental deficit rather than a develop-
mental delay in working memory for children with
PKU [34]. In another study, Ris and colleagues com-
pared the neuropsychological performance of adults
affected by PKU with that of their unaffected siblings
and found that the PKU patients were relatively im-
paired on measures of attention, visual-constructional
ability, and cognitive flexibility [22]. Leuzzi and col-
leagues [15] showed that young subjects with early-
treated PKU performed worse in comparison to age and
IQ matched controls on various tasks including tower
of London (TOL), Visual Search Test, Rey-Osterreith
Complex Figure Test, Weigl’s Sorting Test, and Motor
Learning Test indicating problems with planning and
problem solving, set shifting, selective and sustained
attention and sorting of categories.
In healthy individuals, the activity of the enzyme
phenylalanine hydroxylase (PAH) ensures that Phe
levels are kept in balance. For people with PKU, die-
tary treatment is expected to keep Phe levels within a
safe range, usually between 180 and 480 lmol/l. While
these levels are considerably lower than those seen in
untreated PKU subjects (around 1,200 lmol/l), they
are still three to eight times higher than that found in
people who do not have PKU (around 60 lmol/l: [24,
28]. As Phe, tyrosine (Tyr), tryptophan and other
large neutral aminoacids compete for limited quan-
tities of the same transporter proteins to cross the
blood–brain barrier, the elevated levels of Phe that
arise from the metabolic dysfunction in PKU leads to
inhibited transport and thereby a deficit of tyrosine,
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tryptophan and other neutral aminoacids in the brain
[18, 19]. When Phe levels are only moderately ele-
vated, as found in patients with early and continu-
ously treated PKU, the decrease in the amount of Tyr
and other neutral aminoacids reaching the brain will
be relatively small; however even small decreases in
brain Tyr may affect dopamine metabolism in the
PFC while leaving most areas of the brain unaffected
or much less affected [4].
In a longitudinal study, Diamond and colleagues
[5, 6] found that children with PKU who had been on
dietary treatment since the first month of life and had
blood Phe levels that were approximately 3–5 times the
normal range, displayed impairments on tasks that
required working memory and inhibitory control. They
assessed dorsolateral prefrontal cortical function using
tests of executive function and found that when both
working memory and inhibitory control were required,
children with Phe levels of 360–600 mol/l performed
worse than subjects with Phe levels below 360 mmol/l,
unaffected siblings and age and gender matched con-
trols. This group showed no impairment on any of the
battery of control tasks, most of which required the
functions of the medial temporal or posterior parietal
cortices. Furthermore, the concurrent Phe level corre-
lated highly with performance on the tasks, not only
within the PKU group but also within individual chil-
dren with repeat measures over time. These findings
support the hypothesis that performance is related to
current blood Phe levels at the time of evaluation, as
opposed to mean Phe levels over a wide age range or
during the first month or year of life.
A recent meta-analysis by DeRoche and Welsh [7]
that aimed to identify whether a consistent profile of
deficits in PKU has emerged from data published over
the last 25 years, found moderate effect sizes for
working memory and planning; and larger effect sizes
for measures of inhibition and cognitive flexibility.
The meta-analysis therefore provides some evidence
for specificity of the EF deficits in individuals with
early-treated PKU, with particular weakneses in the
abilities to inhibit and flexibly shift responses.
In this study, we were interested to evaluate the
specific cognitive processes that contribute to clinically
significant individual differences in a group of early-
and continuously treated PKU patients from Iran. In
particular we wished to test the predictions from the
meta-analysis suggesting the presence of EF deficits.
Methods
j Subjects
The sample included 10 children and young adults (8
girls and 2 boys) with early-treated PKU and a group
of 15 age, sex, and IQ matched controls (12 girls and 3
boys). The PKU group were recruited from the data-
base of the PKU Society in Asma Center, Tehran, Iran
and ranged from 6 to 20 years of age (Mean = 13
years and 3 months). Inclusion criteria for the study
were a diagnosis of PKU, treatment started before the
age of 2 years, an initial Phenylalanine level greater
than 1,000 lmol/l (16 mg/dl) and an IQ of at least 80
on the Raven test. The PKU group was compared with
a group of unrelated, normally developing children
and adolescents from a similar socio-economic
background. Individuals in the control group ranged
from 7 to 18 years of age (mean = 10 years and
9 months). Ethical approval was obtained from Dep-
uty of Research, Tehran University of Medical Sci-
ences and informed consent was obtained from all
participants.
j Measures
The child and adult versions of the Raven progressive
matrices were used to estimate IQ in the 6–9 year old
and >9 year old subjects respectively. Since autism
and ADHD are also associated with EF deficits and
both behavioural syndromes are relatively common in
PKU [1, 2], the childhood autism rating scale (CARS)
and Conner’s Parent Rating Scale were used to ex-
clude the two disorders in addition to clinical obser-
vation by an experienced child psychiatrist. The
following set of neuropsychological measures were
used to assess the cognitive profile of patients in the
field of executive functions:
Tower of London (TOL)
In this task participants have to plan and implement
an organized sequence of moves to transform an
initial configuration of disks into a goal state. This test
evaluates the ability to inhibit irrelevant responses, as
well as the ability to generate sub-goals in working
memory. In this study the computerized version was
used. The average number of moves to complete each
set, planning time (time between presenting the discs
and making the first move) and subsequent thinking
time (time spent on executing the plan) were mea-
sured [27].
Continuous performance test (CPT)
CPT is used to measure processes related to vigilance,
response inhibition, signal detection, and sustained
attention. Various CPT tasks all have in common a
series of letter or number/figure presentations in
which the participant is required to make a discrim-
ination between target and non-target stimuli and to
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respond accordingly. The computer-based version
used in this study involves the rapid presentation of
stimuli (a number and a figure, e.g. 3“’, on each
page) for up to 5 min. Total number of stimuli was
120, including 15 targets. Subjects were instructed to
respond only to the target’ stimulus by pressing space
bar key on the computer if both the number and the
figure were repeated on the presentation, and to re-
frain from responding to non-target’ stimuli (the
repeat of either of the number or the figure). CPT
performance measures include correct responses,
omission errors (when the participant fails to respond
to the target stimulus), commission errors (when the
participant responds to a non-target stimulus) and
reaction time (RT). The number of successfully rec-
ognized matches by the subject was recorded at the
end of each experiment.
Stroop test
We used the classic single-task Stroop test and not the
intermixed ink-color/word-reading trials, which more
exactly assesses the set-shifting paradigm. The colour-
word-interference-task (CWIT) according to Stroop,
is a classical experimental paradigm used in behav-
ioral neuroscience to assess attention, set-shifting,
inhibitory control and cognitive flexibility. It consists
of three parts: reading the colour of dots (Dots Card);
colour naming (Words Card); and the interference
task (Colours Card). Subjects note the strong inter-
ference of word reading with the third card which is
called the Stroop interference effect. The number of
errors and the time required for reading each card
were recorded for each subject. The difference be-
tween the time of reading the third and the first card
was used as a variable, called Difference Index’ [30].
j Procedure
All participants were examined in the neuropsychol-
ogy laboratory of the Institute for Cognitive Science
Studies in Tehran. In each session, after completing a
demographic questionnaire for the participant, the
Raven Intelligence Scale was performed. A battery of
TOL, CPT, and Stroop was then applied. In patients
with PKU, the concurrent blood Phe and Tyr levels
were also determined by obtaining a 2 ml venous
blood sample on the day of neuropsychological test-
ing.
j Statistical analyses
Data were analyzed using SPSS 11.5. The independent
sample t test was applied to determine statistically
significant group differences on demographic vari-
ables and IQ. Cognitive task variables were compared
between the two groups using the non-parametric
Mann–Whitney U test because of the small sample
size. Spearman’s rank correlation coefficient was ap-
plied to the neuropsychological variables as well as to
the IQ and biochemical measures.
Results
Characteristics of participants in terms of age and IQ
are listed in Tables 1 and 2. Mean age at diagnosis in
the PKU group was 6.8 months (range 0.5–24 months;
SD = 7.78). Mean age at initiation of treatment (i.e.
low-Phe dietary control) was 7.20 months (range 0.5–
24 months; SD = 7.75). Nine out of ten parents in the
PKU group had consanguineous marriage; five were
first cousins and four were 2nd or 3rd cousins. Family
history of PKU was positive in seven of the ten fami-
lies. Results of the CARS and Conner’s questionnaires
did not fall above threshold for either autism or ADHD
in any of the participants and was consistent with
clinical observation. There were no statistically sig-
nificant group differences for any of the demographic
variables (Table 1). The mean IQ score was however
lower in the PKU group compared to the control
group with a trend towards significance (P = 0.06).
j Group differences in cognitive measures
TOL
Results of TOL task are shown in Table 3. No signif-
icant difference was found between the two groups in
Table 1 Descriptive characteristics of the participants
Variables Group P-value
PKU (n = 10) Control (n = 15)
Mean Range SD Mean Range SD
Age (months) 159.30 79–238 49.61 129.33 94–205 28.68 0.06
Full scale IQ 108.40 90–128 12.44 115.33 106–126 4.95 0.06
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terms of the number of moves. With regard to plan-
ning and executing time, there were significant dif-
ferences between the two groups at the movement
levels of 2, 3, and 4 (P < 0.05).
CPT
The number of commission errors was not signifi-
cantly higher in PKU patients; however subjects with
PKU showed significant impairment in terms of the
number of omission errors (P = 0.005). With regard
to mean reaction time, there was no significant dif-
ference between the two groups. Finally, the number
of successfully recognized matches was greater in the
control group (P = 0.005) (Table 4).
Stroop task
In the single-task Stroop test there was no significant
difference between the two groups regarding the time
taken to read the Dots Card and Words Card. Mean
time spent to name the Colours Card was higher in
Table 2 Detailed characteristics of the patients
Age (month) Gender IQ Current
Phe (lmol/l)
Age at Diagnosis
(month)
Onset of low-Phe
regimen (month)
Case 1 92 M 91 704 0.5 1
Case 2 79 F 128 1,418 9 9
Case 3 205 F 112 1,402 1.5 1.5
Case 4 145 M 120 1,207 1.5 1.5
Case 5 204 F 115 2,025 0.5 0.5
Case 6 138 F 109 1,600 24 24
Case 7 174 F 110 704 5 7
Case 8 156 F 113 1,487 1.5 1.5
Case 9 238 F 90 1,400 15 15
Case 10 162 F 96 1,691 10 11
Table 3 TOL task performance
PKU group Control group P-value
Mean SD Mean SD
Average number of moves to complete
2-move problems 2.3 0.51 2.3 0.83 0.76
3-move problems 4.12 1.12 3.96 1.27 0.68
4-move problems 8.85 3.38 6.88 2.10 0.09
5-move problems 10.47 4.24 9.11 3.55 0.42
Planning times (s)
2-move problems 7.14 3.43 3.80 1.13 0.004
3-move problems 10.84 8.19 6.04 1.92 0.01
4-move problems 9.45 8.78 4.90 1.04 0.03
5-move problems 8.38 4.29 6.09 2.12 0.16
Subsequent thinking times (s)
2-move problems 17.16 8.03 11.16 11.25 0.005
3-move problems 32.11 19.66 20.06 11.21 0.10
4-move problems 60.69 27.46 30.88 12.36 0.01
5-move problems 71.68 31.18 45.70 26.23 0.09
Table 4 CPT task performance
PKU group Control group P-value
Mean SD Mean SD
Commission errors (number) 5.50 3.59 3.93 2.31 0.33
Omission errors (number) 4.80 2.97 1.73 1.83 0.005
Mean reaction time (s) 0.79 0.22 0.73 0.10 0.72
Successfully recognized matches (number) 67.7 19.90 88.2 12.26 0.005
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PKU subjects but this was not significant (P = 0.07).
The number of errors in the interference task was not
noticeably higher in the PKU group. Finally the dif-
ference Index was greater in the PKU group that was
not significant (P = 0.31) (Table 5).
j Relationship between biochemical indices, IQ, and
cognitive functions
To control for the potential effect of IQ on executive
functioning, the analyses were controlled for IQ. No
significant correlation was found between IQ and EF
scores in any of these analyses. In addition, there was
no significant correlation between IQ and concurrent
serum Phe level (r = 0.20). To examine the associa-
tion between performance on the cognitive tasks and
the metabolic measures in the PKU group, we calcu-
lated Spearman correlations between the variables
and concurrent Phe levels as well as Phe to Tyr ratio
(Phe/Tyr). We found that none of the pairwise com-
parisons showed significant correlations (Table 6).
Discussion
Executive dysfunction is the most commonly reported
deficit in children with early-treated PKU [5, 28], al-
though some conflicting findings exist [8, 17]. We
examined whether a group of early-treated children
and adolescents with PKU who remained on dietary
treatment showed any evidence of deficits on selected
tests of executive functions. PKU participants in this
study had lower IQ compared to controls, albeit
within the normal range; a finding that is in accor-
dance with previous reports [5, 32]. For example,
results from the longitudinal PKU Collaborative Study
indicated that early dietary treatment is related to
intellectual levels in the normal range, however,
children with PKU often do not achieve IQ levels
predicted from the scores of unaffected parents and
siblings [33].
In this study, using the TOL task we demonstrated
various levels of impairment in the PKU group. In
particular, planning time and subsequent thinking
time were one to four times higher than that seen in
the comparison control group. Prolonged planning
time at the first three levels of the TOL task indicate
that the PKU patients spent more time figuring out or
deciding which movements to make, which led to
poorer overall results, lower number of moves and
subsequently reduced thinking times. Prolonged
subsequent thinking time might be related to an
impairment in proper planning and number of
movements; therefore subjects require online plan-
Table 5 Stroop Test Performance (Single-task)
PKU group Control group P-value
Mean SD Mean SD
Time in dots card (s) 19.32 7.79 15.68 4.81 0.28
Errors in dots card (number) 0.11 0.33 0.13 0.35 0.95
Time in word card (s) 31.33 18.45 23.82 7.21 0.48
Errors in word card (number) 0.11 0.33 0.07 0.25 0.86
Time in color card (s) 41.77 15.73 30.09 10.89 0.07
Errors in color card (number) 0.33 0.70 0.27 0.59 0.90
Difference index 22.78 11.87 14.41 8.46 0.31
Table 6 Association between executive function variables and biochemical
indices
Phe level Phe/Tyr ratio
TOL
Average number of moves to complete
2-move problems 0.17 )0.2
3-move problems )0.14 )0.32
4-move problems 0.06 0.36
5-move problems 0.23 0.00
Planning times (s)
2-move problems )0.09 )0.2
3-move problems 0.08 )0.42
4-move problems 0.17 )0.41
5-move problems )0.01 )0.43
Subsequent thinking times (s)
2-move problems 0.07 )0.35
3-move problems 0.03 )0.43
4-move problems 0.3 0.09
5-move problems 0.4 )0.09
CPT
Commission errors (number) 0.27 0.08
Omission errors (number) 0.15 )0.49
Mean reaction time (s) )0.03 0.07
Successfully recognized matches (number) )0.15 0.49
Stroop task
Time in dots card (s) 0.02 )0.51
Errors in dots card (number) 0.27 )0.41
Time in word card (s) 0.03 )0.33
Errors in word card (number) )0.27 0.13
Time in color card (s) 0.2 0.02
Errors in color card (number) 0.43 0.27
Difference index 0.41 0.41
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ning for problem solving. Improper planning and
movement prediction therefore calls for additional
moves to solve the problem. Our findings reproduced
part of the study by Welsh and colleagues that showed
impairment of executive functions in 11 pre-school
early-treated PKU children compared to age- and IQ-
matched unaffected peers using EF measures such as
Tower of Hanoi, Motor Planning and Visual Search.
They did not find any group differences in non-
executive function tasks such as recognition memory.
It was shown that performance on executive function
tests was inversely related to concurrent Phe level and
more weakly it was related to mean lifetime Phe levels
[31].
Our study showed that PKU subjects performed
more poorly than controls on CPT. Comission errors
(the index of impulsivity) were not significantly dif-
ferent between two groups, however the number of
successfully recognized matches was significantly
lower and omission errors (the index of attention or
working memory) was significantly greater in PKU
patients compared to controls.
We did not find any significant differences between
two groups on the single-task Stroop test which might
be a result of not having a task-switching block; there
may have been differences if an intermixed ink-color/
word-reading trial in the same block was available.
What seems really difficult in overcoming one’s
inertial tendency to continue in the same mindset, is
switching between one mental set and another, pro-
posed by some researchers to replace the classic sin-
gle-task Stroop test [3].
There are many discrepancies in the findings
regarding phenylalanine levels across previous stud-
ies, although the reasons for this remain unclear. This
could be due to differences in the cognitive domains
evaluated, task specific factors, the age of participants,
phenylalanine level or the quality of strict dietary
control [34]. In this study, we did not find any evi-
dence of a relationship between cognitive perfor-
mance and biochemical measures (i.e. Phe level and
Phe/Tyr ratio) as all correlations were non-significant.
This might be attributable to the fact that blood Phe
levels are poor indicators of brain Phe levels [13]. Low
statistical power of the sample studied may also have
limited the capacity to detect significant correlations.
Luciana and colleagues assessed EF and non-EF
functions in 18 PKU-affected adolescents with normal
IQ, in comparison to unaffected peers and chronically
ill controls. Although the overall performance of the
PKU group did not differ from that of the other two
groups, the proficiency of the PKU group in a number
of tests of executive and non-executive functions was
associated with the concentrations of Phe and Tyr and
most strongly with Phe to Tyr ratios measured at
several points in development. Luciana introduced
the ratio (Phe/Tyr) as one of the best indicators of
dopamine availability in PKU [16]. However, in the
study by White and colleagues in the field of working
memory, no significant correlation between concur-
rent Phe levels and cognitive performance was re-
ported [34].
Most studies of executive function in early and
continuously treated PKU have focused on a limited
age group (infants, preschoolers, adolescents or
adults). Unfortunately, as the PKU screening program
has not been widely instituted in Iran, there are not
many treated PKU patients with normal IQ and we
had to accept a wide age range. Moreover, due to poor
follow-up of PKU patients by their clinics, some
clinically relevant data (such as the mean level of Phe
throughout their dietary control) was lacking. This
sample could therefore be heterogeneous in this re-
gard (Table 2). The study subjects were not randomly
selected, and the sample was quite heterogeneous in
terms of Phe levels and patients’ treatment history
(i.e. the age at which their dietary treatment was
implemented; duration of treatment; and quality of
Phe control). Given the range of treatment histories
and the small sample size it is difficult to control for
these potentially confounding variables by applying a
multivariate analysis. These considerations increase
the chance that our sample lacked power because of
small sample size and that some of the correlations,
while not reaching statistically significant levels, could
still reflect positive rather than negative findings.
j Clinical and research implications
Overall, our findings based on a sample from Iran, a
very different population from that used in previous
studies, are consistent with previous reports regard-
ing the magnitude and pattern of neuropsychologic
impairments in patients with early treated PKU. These
findings contribute to the emerging literature that
indicates the need to continue Phe-free diets for
longer periods. Our PKU subjects performed worse in
comparison to age-, sex- and IQ-matched controls on
various tasks reflecting executive function procesess
such as planning, problem solving, and attention.
These results do not however imply a selective
impairment of executive functions since other non-
executive functions were not investigated in our
sample. Previous research suggests that the observed
deficits in executive functions are not absolutely
irreversible, even in adults who have been off the
dietary treatment for some time [23].
One limitation of this study is that we did not
evaluate the association between mental state changes
and the Phe-free diet, which might be important in
ruling out comorbid psychiatric disorders that could
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also lead to EF impairments. The results of studies in
this area also indicate that future studies could use-
fully investigate detailed aspects of both EF and non
EF deficits in PKU. Future longitudinal investigation
with a larger sample size is required for a better
understanding of the etiology of these deficits, and
their relationship to treatment history. Designing a
study to examine whether executive dysfunction is
developmentally stable over time in a more homoge-
nous group of early and continuously treated PKU
will help us to see if the pattern of dysfunction is a
developmental delay or deficit. Moreover, large-scale
studies are needed, in comparison to other neurode-
velopmental disorders like ADHD and autism, before
further elaborating on these findings as being specific
to PKU. Results of such studies can hence help to
determine cut-off points for the dietary recommen-
dations and for optimal Phe levels even at different
age groups.
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